Objective: To identify the features of concurrent hepatitis C virus (HCV) infection in liver biopsies from patients thought to have alcoholic liver disease.
Patients: Fifty-five patients with a history of excess alcohol consumption were studied.
Methods: All patients underwent liver biopsy.
Results: Eight of the 55 patients studied were found to be HCV-positive.
Conclusion: The histological features found to be most useful for identifying concurrent HCV infection were the presence of lymphoid aggregates in portal tracts (predictive value 100%), the presence of lymphocytes in the lobules (predictive value 83%), and the pattern of fibrosis, particularly periportal spurring rather than perivenular fibrosis (predictive value 75%).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Flaxseed powder supplementation in non-alcoholic fatty liver disease: a randomized controlled clinical trial.
Food Funct
January 2025
Lianshui People's Hospital Affiliated to Kangda College of Nanjing Medical University, Huai'an, Jiangsu, 223400, China.
: Non-alcoholic fatty liver disease (NAFLD) has become a growing public health problem worldwide, and dietary interventions have important potential in the prevention and treatment of NAFLD. Moreover, previous animal studies have shown that flaxseed has a good improvement effect in animal NAFLD models. : Assess whether flaxseed powder could improve the liver lipid content in patients with NAFLD.
View Article and Find Full Text PDFThe association between working hours and working type with non-alcoholic fatty liver disease: results from the NHANES 1999-2014.
Front Endocrinol (Lausanne)
January 2025
Department of Pediatric Laboratory, Affiliated Children's Hospital of Jiangnan University, Wuxi Children's Hospital, Wuxi, Jiangsu, China.
Background: Previous research has indicated that long working hours are connected to a variety of health conditions, including nonalcoholic fatty liver disease (NAFLD). However, this association which has been observed in more population is limited. Our research is designed to evaluate the association between working hours, working type, and NAFLD.
View Article and Find Full Text PDFExploring the links between gallstone disease, non-alcoholic fatty liver disease, and kidney stones: A path to comprehensive prevention.
World J Gastroenterol
January 2025
Université de Bourgogne, Institut Agro-INRAe, Dijon 21000, France.
The recent study exploring the bidirectional associations between gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease highlights a critical concern in chronic disease management. Given the rising global prevalence of these conditions, understanding their interconnections is essential. The study emphasizes the importance of shared risk factors, such as obesity, type 2 diabetes, dyslipidemia, and oxidative stress, and calls for multidisciplinary screening strategies.
View Article and Find Full Text PDFExploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders.
World J Gastroenterol
January 2025
School of Health Sciences, Universidad Internacional de La Rioja, Logroño 26006, La Rioja, Spain.
This article comments on the work by Soresi and Giannitrapani. The authors have stated that one of the most novel and promising treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) is the use of glucagon-like peptide 1 receptor agonists, especially when used in combination therapy. However, despite their notable efficacy, these drugs were not initially designed to target MASLD directly.
View Article and Find Full Text PDFElafibranor, a dual PPARα and PPARδ agonist, reduces alcohol-associated liver disease: Lessons from a mouse model.
World J Gastroenterol
January 2025
Carmen Laboratory, INSERM Unit 1060-Lyon 1 University, Pierre Benite 69310, France.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent liver pathology in need of novel pharmacological treatments to complement lifestyle-based interventions. Nuclear receptor agonists have been under scrutiny as potential pharmacological targets and as of today, resmetirom, a thyroid hormone receptor b agonist, is the only approved agent. The dual PPAR α and δ agonist elafibranor has also undergone extensive clinical testing, which reached the phase III clinical trial but failed to demonstrate a beneficial effect on MASLD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!